ALRN-6924 produced disease control and objective responses in various TP53-WT tumor patients, and its low hematopoietic toxicity provides a basis for clinical trials of ALRN-6924 as a chemoprotective drug for TP53 mutant cancer patients. This evidence concerns the gene TP53 and neoplasm.